Key result
MAFLD linked to up to ~48% higher 12-year incident CVD risk in women and men.
Why the study?
Does metabolic-associated fatty liver disease (MAFLD) increase the risk of incident cardiovascular disease and mortality in men and women?
Cohort (n=7,101)
Does metabolic-associated fatty liver disease (MAFLD) increase the risk of incident cardiovascular disease and mortality in men and women?
Answers are grounded in this paper and cite their sources.
MAFLD is associated with an increased risk of incident cardiovascular disease in both sexes, with women facing a greater relative risk of cardiovascular events and mortality compared to men.
BACKGROUND AND AIMS: Considering recent revisions in the nomenclature for fatty liver disease, alongside limited data on sex-specific differences in its cardiovascular/mortality outcomes, this study aims to investigate the prevalence and impact of metabolic-associated fatty liver disease (MAFLD) on cardiovascular disease (CVD) and mortality in men and women over a 12-year follow-up period. METHODS: In this large population-based cohort study, 7101 individuals aged ≥ 30 were enrolled. The prevalence of MAFLD was investigated in both genders. After excluding individuals with a history of previous CVD, 6331 participants were followed up for CVD and mortality over 12 years. Steatosis was defined as fatty liver index (FLI) ≥ 60. Multivariate-adjusted hazard ratios (HRs) were calculated for CVD and mortality. RESULTS: The prevalence of MAFLD was 43.2%, higher in men (46.5%) than women (40.6%). Men with MAFLD (47.7 ± 12.1) were younger than women (52.2 ± 11.1). In the 12-year follow-up of 6331 individuals, multivariable-adjusted CVD HRs for MAFLD were 1.36 (1.10-1.67) in men and 1.48 (1.16-1.88) in women. Adjusted mortality HRs were 1.17 (0.86-1.59) and 1.38 (1.00-1.91) in men and women, respectively. Among patients with MAFLD, a subgroup with diabetes faced the highest hazard for CVD and mortality. CONCLUSION: This study found that MAFLD is more common in men at a younger age. Despite the higher prevalence in men, women with MAFLD face a greater risk of cardiovascular events and mortality. Findings highlight the importance of gender-specific considerations in primary prevention programmes for MAFLD-related cardiovascular disease and mortality.
No takes yet. Share an insight, caveat, or question.
Abbaszadeh et al. (2025) conducted a cohort in Metabolic dysfunction-associated fatty liver disease (MAFLD) (n=7,101). Metabolic-associated fatty liver disease (MAFLD) vs. No MAFLD was evaluated on Incident cardiovascular disease (CVD) in women (HR 1.48, 95% CI 1.16-1.88). Metabolic-associated fatty liver disease increased the 12-year risk of incident cardiovascular disease in both men and women.
Synapse has enriched 10 related papers. Consider them for comparative context: